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Abstract
Background: Major depression is the leading cause of non-fatal disease burden. Because major depression is not a
homogeneous condition, this study estimated the non-fatal disease burden for mild, moderate and severe
depression in both single episode and recurrent depression. All estimates were assessed from an individual and a
population perspective and presented as unadjusted, raw estimates and as estimates adjusted for comorbidity.
Methods: We used data from the first wave of the second Netherlands-Mental-Health-Survey-and-Incidence-Study
(NEMESIS-2, n = 6646; single episode Diagnostic and Statistical Manual (DSM)-IV depression, n = 115; recurrent
depression, n = 246). Disease burden from an individual perspective was assessed as ‘disability weight * time spent
in depression’ for each person in the dataset. From a population perspective it was assessed as ‘disability weight *
time spent in depression *number of people affected’. The presence of mental disorders was assessed with the
Composite International Diagnostic Interview (CIDI) 3.0.
Results: Single depressive episodes emerged as a key driver of disease burden from an individual perspective.
From a population perspective, recurrent depressions emerged as a key driver. These findings remained unaltered
after adjusting for comorbidity.
Conclusions: The burden of disease differs between the subtype of depression and depends much on the choice
of perspective. The distinction between an individual and a population perspective may help to avoid
misunderstandings between policy makers and clinicians.
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Background
Depressive disorders affect 15 % of the population on a
lifetime basis [1] and have a detrimental impact on so-
cial, family and professional role functioning [2–5]. De-
pression however, is not a homogeneous condition and
its burden of disease might vary across Diagnostic and
Statistical Manual (DSM)-IV subtypes.
Subtypes of depression can be classified into single
episode or recurrent depression and then further graded
by severity: mild, moderate or severe [6]. Burden of disease
estimates for subtypes of depression have received remark-
ably little attention in research. Kruijshaar et al. [7] studied
the associations of severity and type of depression with
functional impairment of the individual in a Dutch general
population sample. They concluded that recurrent de-
pression was found not to be associated with more im-
pairment than single episode depression. Higher severity
classes however were associated with more impairment. In
contrast, Vos et al. [8] arrived at the conclusion that recur-
rent depressions are associated with a greater burden of
disease.
It should be noted that burden of disease can be
assessed at the individual and at population level. At in-
dividual level, clinicians tend to give priority to the dis-
orders that exact the heaviest toll on their patients while
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from a population perspective the disease burden might
be driven by the number of people affected in addition
to case severity and disease duration. Indeed, a study by
Lokkerbol et al. [9] about the non-fatal burden of several
mental disorders showed that the rank order of disorders
by individual burden is often different from the rank order
which is based on the population-level disease burden.
This current study aims to estimate the non-fatal burden
of disease for subtypes of depression from both an individ-
ual and population perspective. Distinguishing both per-
spectives may clarify discussions about resource allocation.
In addition, we take into account the impact of comorbid-
ity. Estimating the disease burden with and without adjust-
ing for comorbidity addresses two fundamentally different
questions. When adjusting for comorbidity, one addresses
an (academic) question about a disorder’s unique contribu-
tion to the disease burden overall. When also incorporating
the additional disability weights of comorbid conditions
one addresses a (pragmatic) question how much people
suffer from a disorder while taking the realistic perspective
that in real life people are not adjusted for comorbidity.
Taking these notions as starting points, we hypothesised
that from an individual perspective, single and recurrent
depressive episodes exact the same toll on individual
patients (H1). However, when assessed from population
perspective, we hypothesised that recurrent depression
would emerge as health care priority due to the large
number of people affected by recurrent depressions (H2).
After all, some 45 % of the depressed people experience re-
currences, usually cumulating to seven or eight depressive
episodes over the course of their life [7] and spending as
much as 21 % of their lifetime in a depressed condition [8].
We also hypothesised that the non-fatal burden of disease
of depression follows the gradient of symptom severity
(H3). Finally, due to comorbid conditions that may lend
extra weight to the burden of disease, we hypothesised that
after adjusting for comorbidity, the burden of disease for
major depression is lower for each subtype of depression
(H4). These hypotheses may not be as straightforward as
might seem because it may the combination of severity of a
depression, the duration of episodes (e.g. the duration of
depressive episodes might be shorter in recurrent depres-
sion [10], the number of depressive episodes (first episode
or recurrent episode) and comorbidity that drive the actual
burden of disease. Therefore, an empirical investigation
is required.
Methods
Sample
Data were collected from the first wave (2007–2009) of
the second Netherlands Mental Health Survey and Inci-
dence Study (NEMESIS-2, n = 6646). The methods used
have been described elsewhere in detail [11, 12]. Briefly,
a multistage, stratified random sampling procedure was
applied. A random sample of 184 of the 443 existing
municipalities was drawn. In these municipalities, a ran-
dom sample of addresses of private households from
postal registers was drawn. Based on the most recent
birthday at first contact within the household, an indi-
vidual aged 18–64 with sufficient fluency in the Dutch
language was randomly selected for interview. The study
was approved by a medical ethics committee and re-
spondents provided written informed consent. Selected
households received a letter from the Dutch Minister of
Health, Welfare and Sport, in which the study was ex-
plained and recommended. Households were contacted
by phone or visited in person [if no phone number was
available] at least ten times during November 2007 to
July 2009. The response rate was 65.1 %.
The sample was fairly representative of the general
Dutch population, but males, younger people (especially
in the 18–24 age bracket), people who had attained
fewer years of education, and those not in paid employ-
ment were somewhat underrepresented. Therefore, post-
stratification weights were used in all analyses [11, 12].
After weighting, the sample followed exactly the same
multivariate distribution over age, gender, marital status
and urbanization (stemming from a rural or urban setting)
as the population according to Statistics Netherlands 2013
[13]. 361 Respondents were diagnosed with depression in
the past 12 months according to the Composite Inter-
national Diagnostic Interview (CIDI) 3.0 [14].
Availability of data and materials
The data on which this manuscript is based are not pub-
licly available. However, data from NEMESIS-2 are avail-
able upon request. The Dutch ministry of health financed
the data and the agreement is that these data can be used
freely under certain restrictions and always under supervi-
sion of the Principal Investigator (PI) of the study. Thus,
some access restrictions do apply to the data. The PI of
the study is co-author of this paper and can at all times be
contacted to request data.
At any time, researchers can contact the PI of NEMESIS-
2 and submit a research plan, describing its background,
research questions, variables to be used in the analyses,
and an outline of the analyses. If a request for data
sharing is approved, a written agreement will be signed
stating that the data will only be used for addressing
the agreed research questions described and not for
other purposes.
Measures
The presence of mental disorders (major unipolar de-
pression and comorbid mental disorders) was assessed
with the CIDI 3.0 [14]. The CIDI is developed by the
World Health Organization and is a psychiatric inter-
view generating 12-month and lifetime prevalence rates
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of the DSM-IV mental disorders. The CIDI 3.0 was first
produced in English and underwent a rigorous process
of adaptation to obtain a conceptually and cross-
culturally comparable Dutch version [15, 16]. Clinical
calibration studies in various countries [17] found that
the CIDI 3.0 assesses anxiety, mood and substance use
disorders with generally good validity in comparison to
blinded clinical reappraisal interviews. Studies on earlier
CIDI versions concluded that the CIDI assesses common
mental disorders with generally acceptable reliability and
validity [18, 19]. Comorbid mental disorders included
any anxiety disorder, any substance use disorder, dysthymia
and attention deficit hyperactivity disorder (ADHD). Eating
disorders was not diagnosed in NEMESIS-2. A diagnosis of
bipolar disorder in the last 12 months by definition ex-
cludes the diagnosis of depression in the same period and
was therefore not taken into consideration.
The CIDI diagnostic interview was used to retrospect-
ively classify type of depression (single or recurrent) and
assess the duration (in days), spent in depression in the
last 12 months. Recurrent depression was declared if a
participant had one or more depressive episodes prior to
the episode in the past 12 months. To study comorbidity
and its effects on the burden of disease, we used the CIDI
without imposing the rules for the hierarchy among the
disorders, meaning that if a person manifests with two dis-
orders, we count this as two distinct disorders and not as
a single disorder.
The severity of the depressive episode of the past year
was assessed with the widely used and validated Sheehan
Disability Scale (SDS) [20]. The SDS is a self-report
measure of condition-specific disability and was incorpo-
rated in all diagnostic CIDI sections. It consists of four
questions, each asking the respondent to rate, on a scale
from 0 to 10, the extent to which a particular disorder
‘interfered with’ activities in one of four role domains
(home, work, social, close relationships) during the
month in the past year when the disorder was most se-
vere. ‘Severe’ depression cases score in the range of 7–10
in at least two areas of role functioning. ‘Moderate’ de-
pression cases are those who score 4–6 in any domain.
Remaining cases are defined ‘mild’ [21]. Depression
cases with unspecified severity (missings on all domains
of the SDS, n = 22) were re-scored, using two questions
of the CIDI about possible disruption of work, social
contacts or personal relations (question D28) and/or in
daily routine (question D28a). ‘Severe’ depression cases
score 4 or 5 (D28) and 1 or 2 (D28a). ‘Moderate’ cases
score 3 (D28) and 1or 2 (D28a) or 4 (D28) and 3 or 4
(D28a). Remaining cases are defined ‘mild’.
Disability weights (DWs) are weight factors that reflect
the severity of the disease on a scale from 0 (perfect health)
to 1 (equivalent to death). DWs were obtained from the
Medical Outcome Study Short Form 6 Dimensions (SF-6D)
using Brazier’s algorithm [22], a well-validated algorithm
that was applicable to our data . The SF-6D is a much used
and well-validated instrument to estimate Health Related
Quality of Life valuations (HR QoL) derived from the Med-
ical Outcomes Study (MOS-36) [23]. It is of note that the
SF-6D can describe as many as 18,000 health states, i.e. all
the permutations of the items (1) physical functioning, (2)
role limitations, (3) social functioning, (4) pain, (5) mental
health, and (6) vitality, each of which has five or six possible
answers. Brazier and colleagues used a sub-sample of 249
health states to elicit valuations in a representative sample
(N = 836) from the general public in the UK. During a
personal interview each respondent was asked to value
the selected health states, and valuation was carried out
using the standard gamble method, which was origin-
ally developed by Von Neumann and Morgenstern [24].
In standard gamble, individuals are asked to make a
hypothetical choice between the certainty of living in
that particular health state versus engaging in a treat-
ment entailing a chance of getting well at probability P
and dying at probability 1-P. The idea is that people are
more willing to accept a risky treatment that involves a
higher risk of dying when their HR QoL is poor.
Brazier and colleagues used the health state valuations
obtained in an econometric model to predict the values
of all 18,000 health states that can be described by the
SF-6D and to assess DWs.
Covariates included gender, age and level of education.
Moreover, we adjusted DWs for the presence of comorbid
mental disorders (assessed with the CIDI) and somatic ill-
nesses, which might inflate DWs. These somatic illnesses
were based on self-reports and consisted of a list 17
chronic general medical disorders being treated or moni-
tored by a physician in the 12 months preceding baseline,
such as asthma, COPD, osteoarthritis, heart disease, peptic
ulcer and diabetes. Comparisons between self-reports of
chronic physical disorders and medical records show
moderate to good concordance [25–27].
Metrics of non-fatal disease burden
Individual perspective: Quality adjusted life year (QALY)
decrements
A common metric to describe an individual’s health-
related quality of life is QALY. A QALY gain is the
amount of time (T) spent in a health state, multiplied by
a valuation of that health state. This valuation is called
‘utility’ (U), which is anchored between 0 (‘death’) and 1
(perfect health). Utilities can be rescaled such that a
higher score signifies poorer health and are then called
DWs. In this burden of disease study we base our calcu-
lations on the DWs. As such, the focus of this disease
burden paper is at QALY decrements instead of QALY
gains. To illustrate, living 5 years with a DW of 0.34 is
equivalent to (5*0.34=) 1.7 QALY decrements.
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Population perspective: Years Lived with Disability (YLD)
At population level we are not looking at one single
individual spending time (T) in a certain health state
weighted by a disability weight (DW), but at (N) indi-
viduals spending variable amounts of time, T, in that
health state weighted by DW. This results in YLDs.
The amount of time individuals collectively spend in a
health condition can be described by the number of
person-years (PYRS). When we want to describe the
disease burden of depressive disorder from a population
perspective we compute PYR and multiply these by the
DW associated with that health state: YLD= PYR * DW.
Henceforth, we reserve the terms “QALY decrement”
for disease burden from individual perspective and “YLD”
for disease burden from population perspective.
Analysis
DWs were estimated for the various types and severities
of depression (single, recurrent, single mild, single mod-
erate, single severe, recurrent mild, recurrent moderate,
recurrent severe) in order to estimate QALY decrements
and YLDs. Here, we took two approaches: one without,
and another with adjustments for comorbid mental dis-
orders and somatic illnesses (12-month depression and
12-month comorbid mental disorders).
QALY decrements not adjusted for comorbidity were
computed as the average DW of all respondents in a
certain subtype of depression multiplied by the average
time spent in a depressed health state in the last year.
While this approach may portray a realistic picture of
the disease burden of a disorder, it can be criticised for
overestimating the disease burden attributable to a
disorder when there are comorbid conditions that lend
extra weight to the DW.
QALY decrements adjusted for comorbidity can be
computed in various ways [28]. In this study we
corrected for comorbidity by regressing DWs on all the
depression subtypes, other mental disorders and
somatic illnesses. The regression coefficients were then
interpreted as the DW of one depression subtype
adjusted for comorbid mental disorders and somatic
illnesses. The intercept (constant) in the regression
models could be interpreted as the DW attributable to
unobserved factors affecting HR QoL such as minor
illnesses, accidents and conditions that were not
measured. The DW of a disorder is the base-rate DW
(intercept, a) plus the adjusted DW corresponding to
this disorder (regression coefficient, b), thus: DW= a + b.
In this way, the adjusted DWs were computed for all
subtypes of depression and multiplied by the average
time spent in depressed state to estimate adjusted QALY
decrements.
YLDs not adjusted for comorbidity per subtype were
computed by multiplying DWs by the number of PYRs.
PYRs were calculated as the number of affected people
(1-year prevalence) multiplied by the total time spent
in depression in the last year. To facilitate interpretation,
results were standardised per one million persons, thus
expressed as YLDs/mln.
YLDs adjusted for comorbidity were corrected for
comorbidity by regressing DWs on all the subtypes,
comorbid mental disorders and somatic illnesses.
The Brazier algorithm we used was executed in Excel
(version 11.0 for Windows, 2003) and can be obtained
from John Brazier at Sheffield University. All other analyses
(estimation of DW, QALY, YLD, PYRS and standard errors)
were conducted in Stata (version 10.1 for Windows). As
data were weighted, Stata’s procedure for design-based ana-
lysis and robust statistical techniques based on first-order
Taylor-series linearization method were used to obtain
correct sample errors.
Results
Sample characteristics
Demographic characteristics of the total NEMESIS-2
sample and of the 361 individuals with depression are
shown in Table 1 (weighted). The depressed population
includes more women, is less highly educated than the
total population and suffers significantly more from co-
morbid disorders.
QALY decrements not adjusted for comorbidity
Figure 1 presents the number of affected patients, average
duration of time spent in depression, DWs that were not
adjusted for comorbidity, individual QALY decrements and
YLD per one million for each of the subtypes in the popula-
tion in the last year. The whole depression sample (n = 361)
has, on average, a DW of 0.27 (se 0.010), meaning that
people who meet the criteria for depression have a HR
QoL that is 27 % lower than the non-depressed population.
Single episodes have a longer duration than recurrent de-
pressions (T = 149 and T = 107 days respectively). Regard-
ing QALY decrements, a single episode poses a greater
burden on individuals than a recurrent depressive episode
(QALY= 0.111 and 0.078 respectively). Besides, higher
levels of symptom severity are associated with higher QALY
decrements.
QALY decrements adjusted for comorbidity
Figure 2 presents the results when adjustments are made
for comorbidity. Both unadjusted and adjusted QALY
decrements show more or less the same ranking of results;
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single depression emerges as the leading causes of non-
fatal disease burden (QALY =0.111). It appears that the
adjusted QALYs are lower than the unadjusted QALYs by
18 % on average. The QALYs for single depression became
smaller after adjusting for comorbidity than those for re-
current depression (0.017 versus 0.014 respectively).
YLDs/mln not adjusted for comorbidity
From population perspective, the number of affected
people becomes an important driver of disease burden.
It appears that from a public health perspective recurrent
depression causes a larger disease burden than single epi-
sode depression (YLD/mln = 2782 and 1882 respectively).
Table 1 Characteristics of the total NEMESIS-2 population (n = 6646) and respondents diagnosed with depression
(last year-prevalence, n = 361), weighteda
Total population
Nemesis-2
Depressed population
Nemesis-2
SE
n (percentage) 6646 (100 %) 361 (5,2 %) –
Mean age (years) 41.6 40.2 1.038
Females (%) 49.6 60.2 0.035
Educational level high-cat 4b (%) 28.0 21.45 0.025
Any 12-month anxiety disorder (%) 10.1 40.0 0.031
Any 12-month substance use disorder (%) 5.6 10.5 0.019
Any 12-month somatic illness (%) 31.6 46.9 0.040
Any 12-month dysthymia (%) 0.89 15.4 0.026
Any 12-month ADHD (%) 1.2 2.7 0.010
Mean duration episode last 12 months (days) n/a 120.86 7.15
Single vs recurrent episodes (%) n/a 32.7/67.3 0.038/0.040
Mild vs moderate vs severe (%) n/a 7.6/36.1/56.3 0.015/0.032/0.033
Abbreviations: ADHD Attention Deficit Hyperactivity Disorder, SE standard error, vs versus
aWeighting based on city of residence, part of country (north, south, east, west) and on a specific weight-factor to correct for differences in the response rates in
several socio-demographic groups and in the probability of selection of respondents within households
bHigher professional or university education
Fig. 1 Unadjusted characteristics of burden of disease for subtypes of depression. Number of affected respondents (n), mean time spent in
depression in days (T), disability weight (DW), quality of life decrement (QALY), years lived with disability per 1 million population (YLD) and
standard errors (between parentheses) for major depression and subtypes of major depression; unadjusted for comorbid mental disorders and
somatic illnesses. Standard errors of YLD were calculated using the standard rules when multiplying two variables, under the assumption that
both variables (DW and PYRS/mln) are independent (se YLD/mln = √ ((se DW/DW2) + (se (PYRS/mln)/(PYRS/mln)2))
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Again, higher levels of symptom severity are associated
with a greater burden of disease. Severe single episode and
recurrent depressions emerge as the subtypes associated
with the highest levels of YLD disease burden. Both types
of depression are associated with a relatively large number
of person-years and in addition have a high average DW,
making them both leading causes of disease burden as
seen from a population perspective.
YLDs/mln adjusted for comorbidity
From population perspective, YLDs/mln are on average
15 % lower after adjustment. Comparable to disease bur-
den at individual level, both the unadjusted and adjusted
YLDs show a similar hierarchy: recurrent depression
emerges as the leading cause of non-fatal disease burden
(YLD/mln = 2.267). Single mild depression is the least
disabling condition, mainly due to the small number of
affected people.
Discussion
Main findings
This study estimated the non-fatal burden of disease for
subtypes of depression such as single episode and recur-
rent depression, graded by severity (mild, moderate, se-
vere depression). All estimates were assessed from an
individual or a population perspective. In addition, the
disease burden estimates were adjusted for comorbidity.
We hypothesised that from an individual perspective,
the disease burden of a single depressive episode would
be equal to the disease burden of a recurrent depression.
However, results show that a single episode is associated
with greater non-fatal disease burden than recurrent de-
pression. Apparently, DWs are equal (both 0.27) but the
time spent in recurrent depression versus a single epi-
sode is shorter (107 vs 149 days respectively).
The other three hypotheses were confirmed; from a
public health perspective, recurrent episodes are associ-
ated with greater disease burden (H2). Even though the
mean time spent in a recurrent depression is shorter, the
large number of people affected comes into play (n = 115
single episode and n = 246 recurrent episode). As ex-
pected, the burden of disease follows the gradient of
symptom severity (H3). Finally, the burden of disease for
each subtype of depression is lower after adjusting for
comorbidity (H4).
Context and other studies
We need to place our findings in the wider context of
the literature. Depressive disorder has been consistently
identified as a leading cause of disability [29, 30]. Cur-
rently, depression is the single leading cause of non-fatal
YLD disease burden in high-income countries and it is
projected to become the second leading cause of DALY
disease burden (which also accounts for mortality) by
2020, second only to ischemic heart disease [31]. More
Fig. 2 Adjusted characteristics of burden of disease for subtypes of depression. Overview of number of affected respondents (n), mean time
spent in depression in days (T), disability weight (DW), quality of life decrement (QALY), years lived with disability per 1 million population (YLD)
and standard errors (between parentheses) for major depression and subtypes of major depression; adjusted for comorbid mental disorders and
somatic illnesses. Standard errors of YLD were calculated using the standard rules when multiplying two variables, under the assumption that
both variables (DW and PYRS/mln) are independent (se YLD/mln = √ ((se DW/DW2) + (se (PYRS/mln)/(PYRS/mln)2))
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recent projections predict that depression might become
the single leading cause of DALY disease burden in the
high-income countries by the year 2030 [29]. The Global
Burden of Disease (GBD) studies [32] conducted in 1990
and 2000 have quantified non-fatal health outcomes
across a range of disorders at the global and regional
level. The leading causes of YLDs were much the same
in 2010 as they were in 1990, with depressive disorder
contributing 8.1 % of total YLDs, ranking second after
low back pain. Depressive disorder caused 63 million YLDs
globally, but this figure was not disaggregated across the
various types of depressive disorder. More recently, another
GBD publication [4] showed that depressive disorders
accounted for most YLDs within the group of mental and
substance use disorders (42.5 %, 95%CI: 33.3–51.7)).
Kruijshaar et al. [7] studied the associations of severity
and type of depression with functional impairment of the
individual in a Dutch general population sample. Functional
impairment was defined as limitations in physical, psycho-
logical and social functioning. Impairment was measured
using the Short-Form-36 Health Survey (SF-36) [33] and
two other indicators of impairment were added to reflect
some of the economic consequences of depression as well:
the number of days spent in bed due to psychiatric, drug-
or alcohol-related problems, and the time missed from
work due to these problems. The study did not make a dif-
ference between disability at individual or population level.
They concluded that higher severity classes were associated
with more impairment. However, recurrent depression was
found not to be associated with more impairment than sin-
gle episode depression. In contrast, Vos et al. [8] arrived at
another conclusion. Their study focused on quantifying the
burden of disease currently averted in people seeking care
for major depression and the amount of disease burden
that could be averted in these people under optimal
episodic and maintenance treatment strategies. Results
suggested that recurrent depression is the key driver of
disease burden and that depression should be treated
as a chronic episodic disorder in order to reduce this
great burden of disease.
A study by Lokkerbol et al. [9], aimed at estimating
the non-fatal burden of disease at both individual and
population level due to several mental disorders in a
Dutch population sample, estimated an unadjusted DW
of 0.35 for depression and an adjusted DW of 0.25.
YLD/mln were estimated 9117 and 6524 respectively.
These findings showed that comorbidity plays an import-
ant role in causing disability, analogue to our findings.
Contrary to our findings however, Lokkerbol’s adjusted
and unadjusted DWs and YLD/mln led to different rank
orders. However, Lokkerbol et al. used the first NEMESIS
data [34] and as a consequence, their analyses were based
on DSM-III-R disorders while ours were based on DSM-
IV disorders. The fact that, from an individual perspective,
the burden of disease for single depression decreased
more than the burden of disease for recurrent depression
after adjusting for comorbidity (0.017 versus 0.014 re-
spectively) indicates that single depression is more often
comorbid with other conditions.
Strengths and limitations
The strengths of this study include the population-based
representative dataset on which the analyses are conducted
and using valid instruments like the CIDI and the SDS.
Another strength is that the disability weights were de-
rived from the general population. The most recent GBD
study [35] also accommodated data collection through
population-based household surveys rather than from ex-
pert panels. This is important, because there are several
ways of eliciting these valuations (e.g. from professionals
in the medical field), but these are surrounded by contro-
versy, and ultimately we need to understand how people
value their own health [36].
A third strength is that we could compute both un-
adjusted and adjusted estimates. Unadjusted QALY
decrements and YLDs portray an accurate picture of
the burden of disease in subtypes of people that are likely
to have comorbid conditions—after all, in real life, we do
not encounter people who have been adjusted for comor-
bidity. Therefore, unadjusted estimates may have value
from a public health perspective. However, when the aim
is to assess the burden of disease attributable to a specific
type of disorder, then adjusted estimates are preferred, be-
cause adjusted estimates give information about the level
of disability due to a single disorder. In our study, we ex-
plored both approaches and were thus able to shed light
on the different conclusions that depend on the chosen
perspective.
A final strength is the distinction between a clinical
perspective on individuals and a public health perspec-
tive on populations. This distinction might be important
to inform clinicians, decision makers and researchers in
the health care sector in a conceptually clear and unam-
biguous way.
We acknowledge the following limitations of our study.
First, we used a 1-year timeframe for the analysis of
disease burden. Therefore we might have missed the
intermediate dynamics of incidence, remission and re-
currence within that year. Perhaps more importantly, the
longer-term dynamics of the epidemiology of depressive
disorder beyond 1 year were missed in our study. To il-
lustrate, Vos and colleagues [8] estimated that in people
with a history of depression the risk of a recurrence is
60 % within the 1st year after remission of the index epi-
sode, 70 % after 2 years, 80 % after 20 years and might
be as high as 90 % on a lifetime basis. Despite this limi-
tation, our approach is well-accepted and is used in the
most recent WHO Global Burden of Disease (GBD)
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study [5], which aims to estimate the burden of disease
consistently across diseases, risk factors and regions. To
estimate burden of disease the GBD study was based on
point (current/past month) or past year prevalence esti-
mates and excluded lifetime estimates as recall bias inva-
lidated them as credible measures of disease burden.
Second, we focused on the non-fatal disease burden,
ignoring excess mortality, but elsewhere we computed
that the risk of premature death is a factor 1.65 higher
in people with depression as compared to people without
depression [37]. Especially when taking the life-course per-
spective, mortality may have significant impacts on disease
burden, and these impacts were missed due to our focus
on ‘instantaneous’ non-fatal disease burden.
Third, people with severe conditions may have been
unable to participate in this population-based survey,
because they were hospitalised, and this is likely to have
resulted in an under-estimation of the disease burden
in the more severe forms of depression.
Fourth, we used the Brazier algorithm to calculate util-
ities and disability weights, but this algorithm was based
on health state valuations in a sample of British people,
while our sample was Dutch. This may have distorted our
outcomes somewhat, although it is unlikely to change the
overall results in a material way, as differences in Western
Europe between national value sets, such as the set for the
SF-6D, are small [38]. While we feel that the people should
be the ultimate judges of their own health, a panel of lay-
people may be associated with limitations that are worth
noting, such as lesser consistency, and the possibility that
(healthy) laypeople have difficulties passing judgments on
the severe conditions. This may have caused some errors in
the estimation of the disability weights associated with the
more severe disorders. In fact, regarding the more severe
conditions, Brazier et al. [22] pointed out that ‘inconsistent
estimates (…) of the value of the poorest health states’
might be seen as a limitation of their method.
A fifth limitation is based on the fact that we relied on
the DSM-IV diagnosis of major depression thus to the
exclusion of minor depression which only became recog-
nised as a disorder in the DSM-5. Nevertheless, it should
be noted that minor depression also causes disability and is
more common [39]. This findings may have resulted in an
under-estimation of population estimates of disease burden,
which depends on the proportion of people affected.
The sixth limitation is concerned with the validity of
asking someone who may be depressed about their quality
of life. Their answers may be biased because of the nega-
tive perceptive biases so common in depression. There-
fore, we expect a downward bias in the estimated QALYs
of depressed people and conversely an upward bias in the
estimation of YLD.
A seventh limitation is about the standard gamble
technique. It is a well-tested technique and is consistent
with QALY theory [40]. However, in practice, appropri-
ate adjustments for time preferences (i.e. discounting)
for trade-offs made over a long period of time may be
challenging to apply [41]. This technique may result in a
lack of sensitivity if the respondent does not perceive the
temporary health state as sufficiently impaired to induce
them to trade time from their life or to gamble with a
probability of death. This ‘ceiling effect’ may occur des-
pite the presence of disutility from the impaired health
state [42].
An eighth limitation is that data on somatic illnesses is
based on self-report rather than diagnostic assessment,
as well as the fact that we did not adjust for every illness,
but only for 17 illnesses. This may have inflated DWs
and YLDs estimates for depressive disorder.
A ninth limitation is that we did not adjust for severity
of comorbidity, which might have provided a more real-
istic picture.
A final point: our analyses were performed on a sample
that was diagnosed with depression during the past year,
whereas the MOS SF-36 is designed to assess disability
over the period of the past 4 weeks. The depressive epi-
sode may have occurred well before the last month as the
average duration of an episode is 4–6 months. As a result,
past month level of disability may not be truly representa-
tive for the disability that was actually experienced during
the disorder. The individuals that are no longer suffering
from depression may have therefore contributed to an
underestimation of DWs, QALY decrements and YLDs.
The use of a 12-month timeframe to estimate 1-month
disability has the advantage that remitted disorders which
continue to have residual adverse effects on disability are
included. In sum, we captured the average effect of both
acute and remitted episodes in the past 12 months on
disability.
In this paragraph we mentioned a number of limita-
tions. If these limitations led to bias overall, this bias will
probably have led to an underestimation of the burden
of disease but will probably not (or at least to a lesser
degree) have impacted the ranking of the subtypes of de-
pressive disorder.
Implications
Major depression is a leading cause of non-fatal disease
burden, but it is not a homogeneous condition and
assessing the disease burden for subtypes of depression
and according to a gradient of symptom severity may
help prioritise treatment allocation.
Overall, we saw that the disease burden differs from
one subtype to another and that comorbidity influences
the results. In addition, our study showed that the burden
of depression poses a substantial challenge both from a
clinical perspective (at individual level) as well as seen
from a public health perspective (at population level). This
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justifies the prevailing dichotomy of medicine into clinical
medicine (directed at individual patients) and public health
(directed at collectives). Health care providers who focus
on helping individual patients may conclude from our re-
sults that a single episode depression causes a greater bur-
den of disease than a recurrent depression. However, the
high prevalence of recurrent depression in the population
does raise questions about how to best alleviate the disease
burden stemming from recurrent depression when taking
the public health perspective. The distinction between a
clinical and a public health perspective may cause confu-
sion in debates when not made explicit.
Our message is that individual and population per-
spectives are neither absolute nor independent concepts.
Both perspectives serve different purposes and may re-
quire careful alignment when being used jointly. Such an
alignment may result in the optimal balance between an
individual approach directed, for example, at the epi-
sodic treatment of acute single episode depressions, in
combination with a public health care approach with an
emphasis on the longer-term preventive management of
recurrences.
Conclusions
The burden of disease differs between subtypes of depres-
sion and depends much on the choice of perspective. The
distinction between an individual and a population perspec-
tive may help to avoid misunderstandings between policy
makers and clinicians.
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